X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Orotecan (irinotecan HCl) is a topoisomerase-I inhibitor approved by the FDA. It is now being evaluated for the treatment of recurrent pediatric solid tumors.
Lead Product(s): Irinotecan Hydrochloride,Temozolomide
Therapeutic Area: Oncology Product Name: Orotecan
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2024
Details:
The net proceeds will be used to fund a preclinical study on Glioblastoma (GBM), an incurable brain cancer, to potentially increase the efficacy of Merck's FDA approved drug Temodar (temozolomide).
Lead Product(s): Temozolomide
Therapeutic Area: Oncology Product Name: Temodar
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ludwig Enterprises
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing March 27, 2024
Details:
LAM561 (2-hydroxyoleic acid (2-OHOA); idroxioleic acid, sodium) is a synthetic derivative of oleic acid and the most advanced R&D product which is taken orally. It is being evaluated in combination with TMZ & RT for the treatment of newly diagnosed glioblastoma.
Lead Product(s): 2-Hydroxyoleic Acid (2-Ohoa); Idroxioleic Acid, Sodium,Temozolomide
Therapeutic Area: Oncology Product Name: LAM561
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
LSTA1 (certepetide) is an investigational drug designed to activate a novel uptake pathway that allows co-administered anti-cancer drugs to penetrate solid tumors more effectively. It is being evaluated in phase 2 clinical trials for the treatment of glioblastoma multiforme.
Lead Product(s): Certepetide,Temozolomide
Therapeutic Area: Oncology Product Name: LSTA1
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2024
Details:
The collaboration aims to conduct a Phase 2 clinical trial to evaluate Rezlidhia (olutasidenib) in combination with temozolomide as maintenance therapy in newly diagnosed pediatric and young adult patients with high-grade glioma (HGG) harboring an IDH1 mutation.
Lead Product(s): Olutasidenib,Temozolomide
Therapeutic Area: Oncology Product Name: Rezlidhia
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CONNECT
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 04, 2024
Details:
INB-200 is the first genetically engineered gamma-delta T cell therapy to be administered to patients with solid tumors. It is under phase 1/2 clinical development for the treatment of glioblastoma.
Lead Product(s): Autologous Genetically Modified Gamma-delta T Cells,Temozolomide
Therapeutic Area: Oncology Product Name: INB-200
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
INBRX-109 is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation, which is investigated for Ewing sarcoma.
Lead Product(s): INBRX-109,Temozolomide,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: INBRX-109
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
BDTX-1535, is a EGFR inhibitor (TKI), is under investigation for the treatment of NSCLC harboring intrinsic driver and/or acquired resistance (post-osimertinib) EGFR mutations and glioblastoma multiforme (GBM) with multiple EGFR alterations.
Lead Product(s): BDTX-1535,Temozolomide
Therapeutic Area: Oncology Product Name: BDTX-1535
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
DFMO (eflornithine) is a novel cytostatic agent that irreversibly inhibits ornithine decarboxylase, which is investigated in combination with eflornithine in patients newly diagnosed with glioblastoma.
Lead Product(s): Eflornithine,Temozolomide
Therapeutic Area: Oncology Product Name: DFMO
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
LSTA1 is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate malignant glioma more effectively.
Lead Product(s): LSTA1,Temozolomide
Therapeutic Area: Oncology Product Name: LSTA1
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) is one of Telix's lead therapeutic clinical programs and has been granted orphan drug designation in the United States and Europe for glioblastoma therapy.
Lead Product(s): [131I]Iodo-phenylalanine,Temozolomide
Therapeutic Area: Oncology Product Name: TLX101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2023
Details:
CAN008 (asunercept) is a glycosylation fusion protein that blocks the interaction between the CD95 receptor and its cognate ligand CD95L through binding to CD95L. It is being investigated for glioblastoma multiforme.
Lead Product(s): Asunercept,Temozolomide
Therapeutic Area: Oncology Product Name: CAN008
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 03, 2023
Details:
The net proceeds will be used for the advancement of the Company’s clinical development pipeline, including potential accelerated approval activities for BDTX-1535, targeting MasterKey mutations in both EGFR mutant-positive NSCLC and in glioblastoma multiforme.
Lead Product(s): BDTX-1535,Temozolomide
Therapeutic Area: Oncology Product Name: BDTX-1535
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 29, 2023
Details:
The net proceeds will be used for the advancement of the Company’s clinical development pipeline, including potential accelerated approval activities for BDTX-1535, targeting MasterKey mutations in both EGFR mutant-positive NSCLC and in glioblastoma multiforme.
Lead Product(s): BDTX-1535,Temozolomide
Therapeutic Area: Oncology Product Name: BDTX-1535
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 28, 2023
Details:
BDTX-1535 is designed to be a potent, selective, brain penetrant and irreversible MasterKey inhibitor of EGFR mutations that expressed in glioblastoma multiforme (GBM) and intrinsic and acquired resistance EGFR mutations in non-small cell lung cancer (NSCLC).
Lead Product(s): BDTX-1535,Temozolomide
Therapeutic Area: Oncology Product Name: BDTX-1535
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
BPM 31510, the company’s lead drug candidate, acts by targeting the mitochondrial machinery and tumor microenvironment (TME) to create a metabolic shift in cancer cells, leading to cancer cell death.
Lead Product(s): Ubidecarenone,Temozolomide,Vitamin K1
Therapeutic Area: Oncology Product Name: BPM 31510
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Berg Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2023
Details:
Debio 0123 is a brain-penetrant and highly selective WEE1 inhibitor, it is being investigated in combination with temozolomide (TMZ) in patients with recurrent or progressive glioblastoma and in combination with TMZ/RT (SOC) in newly diagnosed patients.
Lead Product(s): Debio 0123,Temozolomide
Therapeutic Area: Oncology Product Name: Debio 0123
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Details:
INB-400 is an autologous, genetically engineered gamma-delta T cell therapy that was recently cleared by the FDA for a Phase 2 trial targeting newly diagnosed glioblastoma multiforme (GBM).
Lead Product(s): INB-400,Temozolomide
Therapeutic Area: Oncology Product Name: INB-400
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
CAN008 (asunercept) is a glycosylation fusion protein that blocks the interaction between the CD95 receptor and its cognate ligand CD95L through binding to CD95L. It is being investigated for glioblastoma multiforme.
Lead Product(s): Asunercept,Temozolomide
Therapeutic Area: Oncology Product Name: CAN008
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Details:
IGV-001 is an autologous biologic-device combination product derived from Imvax’s proprietary Goldspire™ immuno-oncology platform for solid tumors. Currently it is being developed for newly diagnosed glioblastoma.
Lead Product(s): IGV-001,Temozolomide
Therapeutic Area: Oncology Product Name: IGV-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Details:
CAN008 (asunercept) is a glycosylation fusion protein that blocks the interaction between the CD95 receptor and its cognate ligand CD95L through binding to CD95L. It is being investigated for glioblastoma multiforme.
Lead Product(s): Asunercept,Temozolomide
Therapeutic Area: Oncology Product Name: CAN008
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
Details:
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases.
Lead Product(s): Ibudilast,Temozolomide
Therapeutic Area: Oncology Product Name: MN-166
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2023
Details:
TTP488 (Azeliragon), is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). A broad range of evidence suggests that RAGE ligand interactions play a critical role in cancer and in inflammatory diseases.
Lead Product(s): Azeliragon,Temozolomide
Therapeutic Area: Oncology Product Name: TTP488
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
OKN-007 improves the tumor microenvironment by multiple mechanisms of action, including removal of reactive oxygen species, reducing the levels of both TGF-beta and HIF-1alpha, and by normalizing the blood vessels in the tumor.
Lead Product(s): OKN-007,Temozolomide
Therapeutic Area: Oncology Product Name: OKN-007
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Details:
In the Phase 1b study of IGV-001, multiple efficacy signals were observed including significant improvements in progression-free survival, radiographic evidence of tumor response, and multiple biomarker changes that supported the presence of an immune response.
Lead Product(s): IGV-001,Temozolomide
Therapeutic Area: Oncology Product Name: IGV-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
CAN-2409 (aglatimagene besadenovec) is genetically modified adenovirus that is designed to encode HSV-tk gene, an enzyme that locally converts orally administered valacyclovir into a toxic metabolite that kills infected and nearby cancer cells.
Lead Product(s): Aglatimagene Besadenovec,Valacyclovir,Temozolomide
Therapeutic Area: Oncology Product Name: CAN-2409
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022
Details:
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF).
Lead Product(s): Ibudilast,Temozolomide
Therapeutic Area: Oncology Product Name: MN-166
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
The interim analysis demonstrated that pamiparib is well-tolerated in glioblastoma patients, reaches pharmacologically-relevant concentrations in nonenhancing GBM tissue, and sensitizes brain tumor tissue to radiation ex vivo.
Lead Product(s): Pamiparib,Temozolomide
Therapeutic Area: Oncology Product Name: BGB-290
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ivy Brain Tumor Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2022
Details:
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources.
Lead Product(s): Radium-224,Temozolomide
Therapeutic Area: Oncology Product Name: Alpha Dart
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
Details:
The preliminary clinical results for a phase I b/II study investigating the PARP inhibitor IMP4297 having Senaparib in combination with temozolomide (TMZ) for the treatment of advanced solid tumors.
Lead Product(s): Senaparib,Temozolomide
Therapeutic Area: Oncology Product Name: IMP4297
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2022
Details:
ST101 is peptide antagonist of C/EBPβ with dual MOA, antagonism of C/EBPβ promotes favorable immune tumor microenvironment by inhibiting formation of immunosuppressive myeloid-derived suppressor cells and cytotoxic activity in tumor cells.
Lead Product(s): ST101,Temozolomide
Therapeutic Area: Oncology Product Name: ST101
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate (“TSC”) in newly diagnosed glioblastoma multiforme (“GBM”) patients.
Lead Product(s): Trans Sodium Crocetinate,Temozolomide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Details:
Treatment led to depletion of immunosuppressive myeloid-derived suppressor cells within the tumor microenvironment, suggesting bavituximab may synergistically combine with checkpoint inhibitors.
Lead Product(s): Bavituximab,Temozolomide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Comprehensive Cancer Network
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2022
Details:
Novocure and MSD plan to conduct a double-blind, placebo-controlled study of TTFields concomitant with KEYTRUDA and maintenance temozolomide (TMZ) versus TTFields together with placebo and maintenance TMZ for the treatment of adult patients with newly diagnosed GBM.
Lead Product(s): Pembrolizumab,Temozolomide
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: MSD Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 26, 2022
Details:
DANYELZA® (naxitamab-gqgk), which targets tumors that express GD2, and one product candidate at the registration-stage, OMBLASTYS® (omburtamab), which targets tumors that express B7-H3.
Lead Product(s): Naxitamab,GM-CSF,Temozolomide
Therapeutic Area: Oncology Product Name: Danyelza
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Study had previously reported a median progression-free survival of 17.1 months in newly diagnosed glioblastoma patients in the highest dose cohort treated with IGV-001, compared with 6.5 months in historical standard-of-care-treated patients (P=0.0025).
Lead Product(s): IGV-001,Temozolomide
Therapeutic Area: Oncology Product Name: IGV-001
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
Patients in phase 2 pilot trial 2-THE-TOP of tumor treating fields (TTFields) together with pembrolizumab and temozolomide, showed median progression-free survival of 12.1 months compared with 7.9 months for matched-control patients from EF-14.
Lead Product(s): Temozolomide,Pembrolizumab
Therapeutic Area: Oncology Product Name: Temodar
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2022
Details:
IGV-001 is Imvax’s most advanced product candidate, in development to treat GBM. It has completed a Phase 1a in recurrent glioblastoma and a Phase 1b in newly diagnosed glioblastoma which in total dosed 46 patients.
Lead Product(s): Autologous GBM Cells,IMV-001,Temozolomide
Therapeutic Area: Oncology Product Name: IGV-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
The phase 2 pilot 2-THE-TOP clinical study, evaluating the use of TTFields therapy together with the anti-PD-1 therapy (pembrolizumab) and chemotherapy (temozolomide) for the treatment of newly diagnosed GBM in 25 patients.
Lead Product(s): Temozolomide,Pembrolizumab
Therapeutic Area: Oncology Product Name: Temodar
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2022
Details:
The genesis for the PIRATE trial was based on several preceding clinical trials which have established potential evidence that RRx-001 increases chemotherapy delivery and uptake in tumors.
Lead Product(s): RRx-001,Temozolomide,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: RRx-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Texas Children’s Hospital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 23, 2022
Details:
Preclinical data published for Long-acting recombinant human interleukin-7, NT-I7 (efineptakin alfa), a novel T cell amplifier increases cytotoxic CD8 T cells and enhances survival in mouse glioma models in the Clinical Cancer Research journal.
Lead Product(s): Efineptakin Alfa,Temozolomide
Therapeutic Area: Oncology Product Name: NT-I7
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2022
Details:
Updated data from the phase 2 pilot 2-THE-TOP trial enables synergies between TTFields and immunotherapy agents, particularly pembrolizumab and temozolomide, and median progression-free survival was at least 11.2 months in patients with greater than 9 months of follow-up.
Lead Product(s): Temozolomide,Pembrolizumab
Therapeutic Area: Oncology Product Name: Temodar
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2021
Details:
IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T-cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia.
Lead Product(s): Gamma Delta T-Cell Therapy,Temozolomide,Niraparib Tosylate
Therapeutic Area: Oncology Product Name: INB-100
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2021
Details:
The results demonstrate that CAN008 has excellent safety and tolerability in patients with GBM and could potentially improve the quality life and the survival time of the patients.
Lead Product(s): CAN008,Temozolomide
Therapeutic Area: Oncology Product Name: CAN008
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Apogenix
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2021
Details:
JP001 is a dual autophagy modulator being developed by HebaBiz Biotech, which can improve tumor microenvironment (TME) and increase tumor cells' sensitivity to chemoradiotherapy.
Lead Product(s): Siroquine,Temozolomide
Therapeutic Area: Oncology Product Name: JP001
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnpro Biotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 20, 2021
Details:
IN8bio is conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T-cell product candidates: INB-200 for newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation.
Lead Product(s): Genetically Modified Autologous Gamma-delta T Cell therapy,Temozolomide
Therapeutic Area: Oncology Product Name: INB-200
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: B. Riley Securities
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering July 22, 2021
Details:
INB-200 is the first-in-human trial of a genetically modified gamma delta T-cell therapy used in combination with temozolomide chemotherapy in newly diagnosed Glioblastoma.
Lead Product(s): INB-200,Temozolomide
Therapeutic Area: Oncology Product Name: INB-200
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2021
Details:
Abstract titled "Comprehensive molecular pharmacodynamic assessment identifies response markers of intermediary metabolism associated with BPM31510-IV treatment in advanced glioblastoma multiforme patients" will be presented at the ASCO meeting.
Lead Product(s): Ubidecarenone,Vitamin K1,Temozolomide
Therapeutic Area: Oncology Product Name: BPM31510
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021
Details:
CAN-2409, previously known as gene-mediated cytotoxic immunotherapy (GMCI™), Candel’s most advanced oncolytic viral immunotherapy candidate, is a replication-deficient adenovirus that delivers the herpes simplex virus thymidine kinase (HSV-tk) gene to cancer cells.
Lead Product(s): Aglatimagene Besadenovec,Valacyclovir,Temozolomide
Therapeutic Area: Oncology Product Name: CAN-2409
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2021
Details:
TRIDENT will test the potential survival benefit of Optune concurrent with radiation therapy in newly diagnosed glioblastoma. The experimental group will receive Optune concurrent with radiation therapy and temozolomide for six weeks, followed by Optune and temozolomide.
Lead Product(s): Temozolomide
Therapeutic Area: Oncology Product Name: Temodar
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
